Registry Protocol for the Development of Remote Digital Mobile Physiological Data Collection in Cancer

Inclusion Criteria

• PROJECT I - HEALTHKIT: Individuals who meet at least one of the following criteria: * Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor * Historical diagnosis of primary invasive solid tumor * Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease * Enrolled onto an investigational trial in the early drug development (EDD) Service * Seen in the Memorial Sloan Kettering (MSK) Urgent Care Center (UCC) from 2021 and onwards * Completion of Survivorship Patient Self-Assessment * Adult without a history of cancer < 50 years of age * Adult without a history of cancer >= 50 years of age
• PROJECT I - HEALTHKIT: ≥ 18 years old
• PROJECT I - HEALTHKIT: Own an Apple iPhone with valid iOS operating software
• PROJECT I - HEALTHKIT: Have a registered MSK MyChart account and be willing to download the MSK Remote Monitoring (RM) application onto their personal iPhone
• PROJECT I - HEALTHKIT: Willing and able to provide informed consent and HIPAA authorization for the release of personal health information
• PROJECT II - DIGIT-EX: Individuals who meet one of the following criteria: * Patients at MSK who are: ** Scheduled to undergo any type of bone marrow transplantation (BMT) (Cohort 1) ** Diagnosed with new onset acute myeloid leukemia (AML) and scheduled to initiate antineoplastic therapy (Cohort 2) ** Scheduled to undergo any surgery for prostate cancer (Cohort 3) ** Scheduled to undergo any lung cancer surgery (Cohort 4) ** Scheduled to undergo total neoadjuvant therapy (TNT) for locally advanced rectal cancer (Cohort 5) ** Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6): *** High risk/very high localized, locally advanced prostate cancer *** Biochemically recurrent prostate cancer *** Treatment naïve, low-volume metastatic prostate cancer ** Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7) * Individuals without cancer < 50 years of age (Cohort 8) * Individuals without cancer >= 50 years of age (Cohort 9)
• PROJECT II - DIGIT-EX: 18 to 90 years old at the time of consent
• PROJECT II - DIGIT-EX: Willing and able to download the Withings Health Mate app onto their personal mobile device
• PROJECT II - DIGIT-EX: Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent
• PROJECT II - DIGIT-EX: Willing to provide informed consent

Exclusion Criteria

• PROJECT I - HEALTHKIT: Unable or unwilling to successfully export and/or share physiological data
• PROJECT II - DIGIT-EX: Unable or unwilling to appropriately use digital platforms or devices